New hope for tough ovarian cancers: targeted drug trial shows promise
NCT ID NCT06028932
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This study tests a drug called sacituzumab govitecan in 20 people with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based chemotherapy. The drug works like a guided missile, delivering chemotherapy directly to cancer cells. The main goal is to see how many patients' tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.